Artificial blood is sometimes known as a blood substitute or a blood surrogate. Artificial blood is a novel idea in transfusion medicine in which specially made compounds replace the role of allogenic human blood transfusion by transporting and delivering oxygen in the body. These dark crimson or burgundy blood replacements are frequently derived from RBCs of expired human blood, cow blood, hemoglobin-producing genetically engineered microorganisms, or human placentas. The synthetic haemoglobin molecules have been tweaked to form a strong structure and to function without the protective cover of RBCS.This growth is primarily driven by Rising demand for blood transfusion and Increasing prevalence diseases.
Globally, a noticeable market trend is evident Introduction to new blood technology. Major Players, such as Dextro-Sang Corporation (United States), BioPure Corporation (United States), Sangart (United States), Northfield Laboratories (United States), Baxter International (United States), FluorO2 Therapeutics (United States), Nuvox Pharma (United States), Alpha Therapeutic Corporation (United States) and HemoBioTech (United States) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.
In 2020, NuvOx Pharma Announces Appointment of Jon S. Saxe to Its Board of Directors. Saxe brings to NuvOx many years of experience from the biotechnology, pharmaceutical and venture capital industries. He has served as a director of more than 25 companies and currently is a director of several publicly traded biotechnology companies including Vistagen Therapeutics and DURECT Corporation as well as a number of private companies. He was president of PDL BioPharma Protein and also was president and CEO of Synergen, a biotechnology company purchased by Amgen. Prior to his work at biotech companies Saxe was vice president of licensing and corporate development and head of patent law for Hoffmann-LaRoche Inc., where he worked for 29 years.
- Rising demand for blood transfusion
- Increasing prevalence diseases
- Introduction to new blood technology
- High cost associated with bloods
Growing awareness of blood donation
Shortage of availability of blood
AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.
Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
Against this Challenging Backdrop, Artificial Blood Study Sheds Light on
The Artificial Blood Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Artificial Blood industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
Where Artificial Blood industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.